125 Fortune Boulevard
About Nitto Avecia
With over 25 years of experience in oligonucleotide development and production, and over 1000 sequences manufactured, Avecia has played an integral role in the advancing oligo therapeutic market. Our mission is to continue to build value for our customers, as they progress through drug development into commercialization. And as a member of the Nitto Denko Corporation (www.nitto.com), Avecia is committed to the future of the oligonucleotide market. We are driven by innovative ideas and flexible solutions, designed to provide our customers with the best in service, quality, and technology.
33 Locke Drive
Marlborough, MA 01752
8560 Reading Road
Cincinnati, OH 45215
Tel: (513) 679-3000
Hear more about Avecia's capabilities and what our employees and customers have to say!
15 articles with Nitto Avecia
As the biopharma industry responds to the COVID-19 pandemic, some of the area's companies are at the very frontlines of drug development against the disease, while others play supporting roles for the entire industry. Here's a look.
Nitto Denko Avecia Inc. announced today that Detlef Rethage will step down from the position of President of Nitto Denko Avecia Inc., effective July 16, 2018.
Avecia announced today the opening of a new corporate office in Cambridge, MA, to support its operations and corporate development activities, and to be more accessible to clients.
Nitto Denko Avecia Inc. Acquires The Businesses Of Irvine Pharmaceutical Services, Inc. & Avrio Biopharmaceuticals
Avecia Biotechnology Inc. Has Engaged BioTechLogic as Consultants to Assist in Expanding Its Quality Management System (QMS) and in Preparing for Post Approval Manufacturing
Avecia Biotechnology Inc. Launches pAVEway(TM) - Advanced Protein Expression for the Manufacture of Biopharmaceuticals
Avecia Biotechnology Inc. And TriLink Partner To Offer Seamless Scale-Up In Oligonucleotide Manufacturing